$GH

Tariq Musa sold $18K of GH

Tariq Musa sold 116 shares of Guardant Health, Inc. (GH) at $156.45 on 2026-08-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tariq Musa
Published Aug 18, 2026, 10:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 18, 2026, 11:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
high confidence
Mentioned
$GH
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure updates the record of insider trading activity but does not provide new company performance, guidance, or regulatory/product developments.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and small size suggest limited incremental information.

03

What to watch

The article does not disclose any buy/sell by other insiders, changes in guidance, or operational developments, limiting the ability to connect the sale to new fundamentals.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-18, transaction dated 2026-08-17

Background

The article is a SEC Form 4 insider transaction disclosure for Guardant Health, Inc.

Company-level read

Ticker impact

$GHNeutralHigh confidence
Context

Guardant Health director Tariq Musa filed a Form 4 showing an open-market sale of 116 shares at $156.45 on 2026-08-17.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4 sale.

Evidence & confidence

The filing specifies a pre-arranged Rule 10b5-1 plan and a relatively small transaction size, which typically reduces interpretive weight versus unscheduled sales.

Market effects

No clear sector read-through from a single, small 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even 10b5-1 sales can coincide with internal expectations, so some traders may still watch for follow-on insider activity or changes in trading patterns.

Key entities

  • Guardant Health, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Tariq Musa

    Director who sold 116 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.